Fused 1,4-dihydrodioxin derivatives as inhibitors of heat shock transcription factor 1
US11787786B2 · kind B2 · utility
0Cited by
9References
1Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Aug 19, 2021 |
| Grant date | Oct 17, 2023 |
| Priority date | — |
| Expiry date | Aug 19, 2041 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D491/056
- WIPO fieldOrganic fine chemistry
- WIPO sectorChemistry
Abstract
The present invention relates to compounds of formula I wherein A1, A2 R4 and Q are as defined herein. The compounds of the present invention are inhibitors of heat shock factor 1 (HSF1). In particular, the present invention relates to the use of these compounds as therapeutic agents for the treatment and/or prevention of proliferative diseases, such as cancer. The present invention also relates to processes for the preparation of these compounds, and to pharmaceutical compositions comprising them.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.